Skip Navigation



NDT Advance Access published online on June 14, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfh907
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
20/9/1963    most recent
gfh907v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Michelis, R.
Right arrow Articles by Kristal, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Michelis, R.
Right arrow Articles by Kristal, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org
Received September 14, 2004
Accepted April 20, 2005

Original Articles

Intravenous iron-gluconate during haemodialysis modifies plasma {beta}2-microglobulin properties and levels

Regina Michelis 1, Shifra Sela 2, and Batya Kristal 3*

1 Eliachar Research Laboratory, Western Galilee Hospital, Nahariya, Israel
2 Eliachar Research Laboratory, Western Galilee Hospital, Nahariya, Israel; Bruce Rappaport School of Medicine, Technion, Haifa, Israel
3 Nephrology Department, Western Galilee Hospital, Nahariya, Israel; Bruce Rappaport School of Medicine, Technion, Haifa, Israel

* To whom correspondence should be addressed.
Batya Kristal, E-mail: Batya.Kristal{at}naharia.health.gov.il



  Abstract

Background. Intravenous iron replacement therapy is routinely used for correction of anaemia in patients with end-stage renal failure. Free or labile iron, present both in parenteral iron formulations and in blood of haemodialysis (HD) patients, has the potential to induce severe oxidative processes. This study evaluated the acute in vivo effect of intravenous iron administration on the oxidation of plasma {beta}2-microglobulin ({beta}2m) and on its plasma levels after HD.

Methods. Iron-gluconate was administered intravenously to 14 patients receiving HD with low-flux cellulose-triacetate membranes during the first hour of the 4 h HD treatment. Each patient underwent three different dialysis treatments, during which an infusion of 62.5, 125 or 0 mg (control) of iron-gluconate was administered in random order. Plasma {beta}2m levels and iron parameters were monitored immediately before and after each HD treatment. The molecular isoforms of {beta}2m were studied by two-dimensional gel electrophoresis and western analysis. Levels of oxidized {beta}2m were evaluated by reaction with 2,4-dinitrophenylhydrazine and western analysis.

Results. Both doses of iron-gluconate caused remarkable changes in the molecular properties of {beta}2m, including shift in isoelectric point, molecular mass and degree of oxidation. Iron administration also limited the decline in plasma {beta}2m levels to <7.5%, compared with 27.9±2.7% during HD without iron.

Conclusions. Intravenous iron-gluconate led to a characteristic increase in molecular weight and in negative charge of {beta}2m, both of which can be assumed to be consistent with reduced membrane sieving coefficients and membrane adsorption, and thus with reduced clearance of {beta}2m.

Keywords: advanced glycation end-products; carbonyl; iron-gluconate; low flux; protein oxidation.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin Med ResHome page
A. Hayat
Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease
Clin. Med. Res., December 1, 2008; 6(3-4): 93 - 102.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Cohen-Mazor, S. Sela, R. Mazor, N. Ilan, I. Vlodavsky, A. L. Rops, J. van der Vlag, H. I. Cohen, and B. Kristal
Are primed polymorphonuclear leukocytes contributors to the high heparanase levels in hemodialysis patients?
Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H651 - H658.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
W. H. Horl
Clinical Aspects of Iron Use in the Anemia of Kidney Disease
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 382 - 393.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.